Vaping & Nicotine:
What You're Actually Inhaling

Vaping Isn't Quitting — It's Rebranding

When e-cigarettes arrived in the early 2000s, they were positioned as the clean, modern alternative to smoking — fewer chemicals, no tar, a stepping stone toward freedom from tobacco. That narrative was effective. It was also premature.

What the early marketing skipped over was that vaping had never been studied long-term. The human lungs had never encountered aerosolized propylene glycol, vegetable glycerin, ultrafine metal particles, and synthetic flavoring compounds — not in this form, not in these concentrations, not delivered directly to alveolar tissue thousands of times a day.

By 2019, the consequences started becoming undeniable. A wave of severe, sometimes fatal lung injuries — eventually named EVALI (e-cigarette or vaping product use–associated lung injury) — hospitalized thousands of people across the United States. The CDC confirmed 2,807 hospitalizations and 68 deaths. And those were only the cases serious enough to make it into the reporting system.

Nicotine: The Isolated Compound Problem

The tobacco plant contains hundreds of compounds beyond nicotine — alkaloids like nornicotine, anabasine, anatabine, and myosmine, plus MAOIs (monoamine oxidase inhibitors) and other constituents that modulate how nicotine is absorbed and experienced. Together, they are referred to as whole tobacco alkaloids (WTA).

Isolated nicotine — as found in patches, gums, lozenges, vapes, and pouches — behaves differently. Without the buffering and modulating context of the whole plant, isolated nicotine may be absorbed faster, reach peak plasma concentration more sharply, and drive more intense feedback loops in the brain's reward circuitry.

This is a recurring pattern across pharmacology: isolate one compound from a complex biological matrix, concentrate it, and deliver it via a route the body was never designed for — and the risk profile changes in ways that are not always immediately visible.

Nicotine itself acts on acetylcholine receptors throughout the body — not just in the brain. It affects cardiovascular function (increased heart rate and blood pressure), restricts blood vessels, impacts insulin sensitivity, and during adolescence, disrupts the normal pruning and development of prefrontal cortex circuitry. The adolescent brain is uniquely vulnerable; addiction pathways form more rapidly, and the long-term effects on executive function, impulse regulation, and anxiety are increasingly documented.

What's Actually in the Vapor

E-cigarette aerosol is not water vapor. That visible cloud is a suspension of ultrafine liquid droplets and particles — and the contents depend on the device, the coil material, the temperature setting, and the e-liquid used.

Heavy Metals from the Heating Element

The metal coils used to heat e-liquids degrade with use, leaching particles directly into the aerosol. Studies using mass spectrometry have detected the following metals in e-cigarette vapor:

Diacetyl & "Popcorn Lung"

Diacetyl is a flavoring compound used to produce buttery, creamy, or sweet flavor profiles in e-liquids. It was first linked to a severe, irreversible lung disease — bronchiolitis obliterans — in workers at microwave popcorn factories who inhaled it occupationally. The nickname "popcorn lung" stuck.

In 2015, researchers at Harvard tested 51 flavored e-cigarette products and found diacetyl in 39 of them — including many products marketed with no mention of the ingredient. A related compound, 2,3-pentanedione, was found in 23 products. Both are respiratory toxins.

Bronchiolitis obliterans is a scarring of the small airways that is not reversible. It produces progressively worsening shortness of breath and — in severe cases — requires a lung transplant.

Formaldehyde & Acrolein

At higher power settings — and even at "normal" settings as coils age — e-liquids thermally degrade into formaldehyde, acetaldehyde, and acrolein. Formaldehyde is a Group 1 IARC carcinogen. Acrolein is a lung irritant that damages cilia (the mucus-clearing mechanism of the airways) and has been linked to cardiovascular injury.

Ultrafine Particles

E-cigarette aerosol is dense with ultrafine particles — particles smaller than 100 nanometers. These bypass the normal defensive mechanisms of the respiratory tract and deposit directly in the deepest regions of the lung, where they can enter the bloodstream. The cardiovascular and inflammatory effects of ultrafine particle inhalation are well-documented from air pollution research; vaping delivers them in concentrated form at close range.

EVALI: What the Lung Injuries Told Us

In the summer of 2019, emergency rooms across the United States began seeing young, otherwise healthy people presenting with severe respiratory failure — ground-glass opacities on CT scans, oxygen saturation in the 70s, bilateral pneumonia patterns that didn't respond to antibiotics. Some were on ventilators within days of their first symptoms.

The CDC eventually identified vitamin E acetate — a cutting agent used in black-market THC cartridges — as the primary driver of the outbreak. But the outbreak did not occur in THC users alone, and regular nicotine vape users were also hospitalized. The investigation confirmed that multiple compounds in vaping products can independently cause acute lung injury, and that the long-term effects of even "safe" vaping products remain unstudied.

Zyn and Nicotine Pouches: The New Gateway

As regulatory pressure on flavored vapes increased, the tobacco and nicotine industry introduced a new product category: nicotine pouches. Brands like Zyn, On!, and Velo are small pouches placed between the lip and gum — no smoke, no vapor, no tobacco leaf. Just synthetic nicotine (or extracted tobacco-free nicotine), flavoring, fillers, and pH modifiers.

The marketing has been aggressive and youth-targeted. Flavors include mint, citrus, coffee, wintergreen, and fruit varieties. By 2024, Zyn was selling over 800 million cans annually in the United States, with the fastest growth among 18–24 year olds.

What's Actually in Them

Nicotine pouches are not inert. The oral mucosa is highly permeable — nicotine absorbs directly into the bloodstream without any first-pass metabolism in the liver, meaning the bioavailability is high and the onset is rapid. Repeated gum exposure also raises concerns about gingival recession (receding gums), irritation, and long-term mucosal changes.

Independent testing of pouches has found trace levels of nitrosamines (known carcinogens formed during the manufacturing of nicotine), as well as benzene and formaldehyde-related compounds in some products. Manufacturers are not required to disclose a full ingredient list.

Who Benefits from the Transition?

It is worth asking a structural question: when an industry facing regulatory extinction — cigarettes — reinvents itself under a new brand with a new mechanism and a decade-long safety data gap, who benefits?

Big Tobacco either acquired or invested in the major vaping brands early. Philip Morris purchased Juul's intellectual property antecedents. British American Tobacco entered the vape market through acquisitions. Altria held a 35% stake in Juul. The same companies that spent decades suppressing research on tobacco harm became the primary suppliers of "harm reduction" alternatives.

The nicotine pouch category has followed the same pattern. The addiction is maintained. The format changes. The consumer transitions. The profit flows to the same corporate infrastructure.

This doesn't mean quitting cigarettes by switching to vaping was the wrong choice for anyone — in the short term, the carcinogen load is likely lower. But the framing of vaping as a public health triumph, rather than as a product that needed decades of safety data before mass adoption, deserves scrutiny.

The Therapeutic Nicotine Narrative — What to Make of It

A counternarrative has gained traction in alternative health circles: that nicotine — not tobacco, not cigarettes, but nicotine itself — has therapeutic properties that have been suppressed. Claims have ranged from nicotine's protective effects against COVID-19, to its acetylcholine agonism as a neuroprotective mechanism, to the idea that patches or lozenges used intentionally could support cognitive function and defend against certain toxins.

Interesting pharmacological properties do not make a substance safe for habitual use. Isolated nicotine has documented addiction potential, cardiovascular effects, and — in developing brains — clear developmental risks. These are not disputed in the literature. The fact that nicotinic receptors exist throughout the body does not make delivering an isolated, synthetic stimulant through the skin a health protocol.

Nicotine Patches Marketed as Vaccine & Toxin Detox

The therapeutic nicotine narrative has evolved into a product category: nicotine patches being marketed as a detox tool — promoted as a way to clear spike protein from COVID vaccines, counteract snake venom components, or protect the body from bioweapon exposures.

This is reaching people who are genuinely frightened, genuinely harmed, and looking for real answers. The concerns about what was in those injections are not unfounded. The impulse to seek a counter-measure is understandable. What the nicotine patch does not do is fix any of it.

Nicotine is a synthetic or highly processed isolated alkaloid — a lab-produced chemical, not a whole plant compound. Adding a synthetic stimulant to a body already navigating inflammation, immune dysregulation, or cardiovascular stress does not constitute detox. It adds a pharmacologically active substance with its own cardiovascular effects, adrenal burden, and addiction potential into an already stressed system.

What the Evidence Actually Shows

The pharmacology referenced in these claims is sometimes real. The conclusions drawn from it are not. Here is the honest breakdown.

Supporting Your Body While Weaning

Nicotine withdrawal is physiologically real — driven by downregulation of acetylcholine receptors that were chronically overstimulated. The symptoms (anxiety, irritability, difficulty concentrating, disrupted sleep, increased appetite) are the body recalibrating toward its natural baseline.

What the body actually needs during this window:

• ●Adrenal support through food: Nicotine chronically stimulates the adrenals — withdrawal amplifies the fatigue that was always there underneath it. Pasture-raised animal proteins, especially organ meats, provide the B vitamins, tyrosine, and zinc the adrenals need to stabilize. Moringa leaf (whole dried leaf or leaf powder, not isolated extracts) is one of the most nutrient-dense whole-food sources available — rich in iron, B vitamins, amino acids, and antioxidants — and provides broad nutritional support without concentrating any single compound. Avoid caffeine stacking onto withdrawal — the adrenal burden compounds.
• ●Lung tissue nourishment: The cilia in the airways begin recovering within weeks of stopping. Foods rich in vitamin A (beef liver, egg yolks, cod liver oil) support epithelial repair. N-acetylcysteine (NAC) as a whole food precursor via cysteine-rich foods (eggs, meat, legumes) supports glutathione production and mucus clearance.
• ●Nervous system grounding: The anxiety spike of withdrawal is real. Magnesium-rich foods (pumpkin seeds, dark leafy greens, dark chocolate), consistent sleep rhythms, and outdoor light exposure help regulate the nervous system without adding additional stimulants.
• ●Heavy metal drainage support: For those who have vaped for years, accumulated metal burden from coil degradation is worth considering. Sulfur-rich foods (eggs, garlic, onions, cruciferous vegetables) support the liver's phase II detoxification pathways. Pascalite clay (taken internally) is a traditional binder that supports metal and toxin drainage without mobilizing metals faster than the body can safely clear them. Beets, dark leafy greens, and adequate hydration support lymphatic and biliary drainage.
• ●Movement: Exercise is one of the most effective nicotine craving interrupters studied, likely because it stimulates many of the same dopamine and endorphin pathways that nicotine was hijacking. Even 10–20 minutes of vigorous movement dramatically reduces craving intensity in the short window after it hits.

There Is No Safe Vape

Every version of this story ends in the same place: the delivery mechanism changes, the corporate owner changes, the marketing language changes — but a synthetic, isolated, highly addictive compound is still entering a human body through a lung, a skin barrier, or a mucous membrane.

"Safe" compared to cigarettes is not the same as safe. "Harm reduction" as a permanent lifestyle is not harm reduction — it's managed addiction. The benchmark should be a body free of synthetic stimulants that disrupt the adrenals, cardiovascular system, and developing nervous tissue.

Vaping was sold as the exit. Pouches were sold as the vaping exit. Patches are now being sold as a health intervention. Each format extends the dependency window, generates new revenue, and delays the moment when the body can actually return to its own baseline.